This post by IRMA’s Jim Pickett first appeared on the blog of the HIV Prevention Justice Alliance. The VOICE results are extremely important to the field of new prevention technology research. I hope current/future/much-needed discussions about VOICE don’t get drowned out by the HYPE (yes, all caps HYPE) surrounding the “baby cure” story which has dominated coverage out Read More >>

via PLoS Medicine, by Gordon Mansergh, Beryl A. Koblin, Patrick S. Sullivan Summary Points: Pre-exposure prophylaxis (PrEP) with anti-retroviral (ARV) medications is partially efficacious for preventing HIV infection among men who have sex with men (MSM) and heterosexuals. As PrEP becomes available and prescribed for use among MSM a better understanding of willingness to use PrEP and Read More >>

 via aidsmap, by Gus Cairns How do we stop the hyperepidemic in gay men? A number of presentations at the 19th International AIDS Conference explored the ‘hyperepidemic’ of HIV amongst men who have sex with men, and especially black MSM. A paper presented by Gregorio Millet (pictured above at a White House reception honoring people working in AIDS) showed that, at Read More >>

via Somatosphere, by Marsha Rosengarten One of the more controversial interventions proposed for HIV prevention in those who test HIV antibody negative and perceived to be at risk is pre-exposure prophylaxis (PrEP) – a daily pill comprising one or two antiretroviral drugs manufactured by Gilead Inc. Besides the mixed results from multi-site randomised controlled trials (RCTs) seeking Read More >>

via Leadership, by Winifred Ogbebo *Mentions IRMA advocate Morenike Ukpong!* Like a breath of fresh air, the news that a combination prevention drug would soon hit the Nigerian market is definitely something to cheer about, given Nigeria’s high prevalence of HIV rate, which is said to be second only to South Africa in the African continent. WINIFRED Read More >>

On May 10, 2012 the FDA Antiviral Drug Advisory Committee strongly recommended that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women – particularly gay men and other MSM, serodiscordant heterosexual couples, and other individuals at high risk. It is likely the FDA will follow Read More >>

via Lancet.com, by Salim S Abdool Karim  and Quarraisha Abdool Karim On May 10, 2012, a US Food and Drug Administration (FDA) advisory committee voted in support of the use of tenofovir-emtricitabine for HIV prevention.1 If the FDA, which is scheduled to make its decision by June 15, adopts the committee’s recommendations, tenofovir-emtricitabine will become the first Read More >>

via aidsmap.com, by Roger Pebody Draft UK guidance on fertility treatment says that sperm washing may no longer be necessary for couples where the man has HIV and the woman does not. As long as the man is on effective antiretroviral treatment and unprotected sex is limited to days when his partner is ovulating, “sperm washing may Read More >>

Read this excellent explanation/sumary via Medscape, by Janis C. Kelly The US Food and Drug Administration’s (FDA’s) Antiviral Drugs Advisory Committee has strongly backed approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection.In a marathon 12-hour session, the panel recommended approval of a supplemental indication for Truvada (emtricitabine/tenofovir disoproxil fumarate) for preexposure prophylaxis Read More >>

via PRNewswire In public comments submitted this week, a group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of emtricitabine/ tenofovir disoproxil fumarate (TDF/FTC or Truvada®) as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult men and women. Their comments, submitted in advance of a May 10 Read More >>